International Urology and Nephrology

, Volume 41, Issue 2, pp 341–355

Direct renin inhibitors: ONTARGET for success?

  • Yasmin Pasha
  • Paul Gusbeth-Tatomir
  • Adrian Covic
  • David Goldsmith
Nephrology - Review

DOI: 10.1007/s11255-009-9556-7

Cite this article as:
Pasha, Y., Gusbeth-Tatomir, P., Covic, A. et al. Int Urol Nephrol (2009) 41: 341. doi:10.1007/s11255-009-9556-7
  • 68 Downloads

Abstract

Direct renin inhibitors are the first new class of antihypertensive to emerge since angiotensin II receptor blockers. We discuss their reno- and cardioprotective potential, based on extrapolation from animal models and phase three trials that are currently ongoing. This paper reviews the potential benefits of direct renin inhibitors (DRIs), the only new anti-hypertensive class developed in the last decade, as compared to pre-existing classes of drug inhibiting more downstream, such as Angiotensin Converting Enzyme inhibitors (ACEI), Angiotensin 2 Receptor Blockers (ARBS).

Keywords

ACE-inhibitorAngiotensin II receptor blockerAliskirenChronic kidney diseaseDirect renin inhibitorsRenin angiotensin systemRenin inhibitors

Copyright information

© Springer Science+Business Media, B.V. 2009

Authors and Affiliations

  • Yasmin Pasha
    • 1
  • Paul Gusbeth-Tatomir
    • 2
  • Adrian Covic
    • 2
  • David Goldsmith
    • 3
  1. 1.Chelsea and Westminster HospitalLondonUK
  2. 2.Nephrology Clinic, Parhon University Hospital“Gr.T. Popa” University of Medicine and PharmacyIasiRomania
  3. 3.Renal UnitGuy’s HospitalLondonUK